Detalhe da pesquisa
1.
Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αß+ T cells targeting multiple myeloma.
Blood
; 143(10): 895-911, 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37890146
2.
Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma.
Blood
; 2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38551812
3.
BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Cell
; 146(6): 904-17, 2011 Sep 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-21889194
4.
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma.
Blood
; 141(21): 2599-2614, 2023 05 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36630605
5.
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.
Blood
; 141(14): 1724-1736, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36603186
6.
CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.
Blood
; 141(23): 2841-2852, 2023 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36877894
7.
A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth.
Blood
; 141(4): 391-405, 2023 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36126301
8.
Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma.
Cancer
; 130(3): 421-432, 2024 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37846845
9.
Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma.
Blood
; 139(16): 2471-2482, 2022 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35134130
10.
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
Blood
; 140(11): 1229-1253, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35653592
11.
Role of minimal residual disease assessment in multiple myeloma.
Haematologica
; 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38328864
12.
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis.
Haematologica
; 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38299578
13.
Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma.
Am J Hematol
; 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38747543
14.
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
Am J Hematol
; 99(4): 523-533, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38247315
15.
Tetraspanin CD82 Correlates with and May Regulate S100A7 Expression in Oral Cancer.
Int J Mol Sci
; 25(5)2024 Feb 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38473906
16.
Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia.
Int J Cancer
; 152(9): 1947-1963, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36533670
17.
Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
Cancer
; 129(14): 2179-2191, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37021929
18.
IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM.
Blood
; 138(20): 1980-1985, 2021 11 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34792571
19.
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
Blood
; 138(20): 1966-1979, 2021 11 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34132782
20.
miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms.
Blood
; 137(14): 1905-1919, 2021 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33751108